---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-047890"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T09:51:28.103199+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nektar shareholders approve authorized share increase to 390M and reverse split authorization

## Summary
- Proposal 5: authorized common shares increased from 300M to 390M (92.5M for, 55.5M against).
- Proposal 6: Board authorized to effect reverse stock split at ratio 1:2 to 1:40 within one year (140M for).
- Proposal 2: 2017 Performance Incentive Plan amended to add 6M shares (72.4M for, 28.8M against).
- Directors Diana Brainard and R. Scott Greer elected; other directors continue.
- Ernst & Young ratified as auditor; say-on-pay advisory resolution passed.

## SEC filing metadata
- accession: 0001213900-25-047890
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025047890/0001213900-25-047890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025047890/ea0243394-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-047890
- JSON: https://secwatch.observer/filing/0001213900-25-047890.json
- Plain text: https://secwatch.observer/filing/0001213900-25-047890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.